Reduced expression of FTO in HCC cells and tissues leads to the accumulation of m6A in HCC and is associated with poor patient prognosis, and it may serve as a novel biomarker for HCC (Zhao et al., 2019a). This evidence concerns the gene FTO and hepatocellular carcinoma.